Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes
November 15th 2016Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.
Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma
November 12th 2016Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.
Dr. Albertsmeier on the Effect of Radiation on Local Recurrence and OS in Soft Tissue Sarcoma
November 10th 2016Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses a a meta-analysis of the effect of radiation therapy on local recurrence and overall survival in patients with soft tissue sarcoma.